• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Optimi Health Corp (CSE:OPTI)

    8.250 +0.410 (+5.23%)
    Streaming Delayed Price Updated: 3:02 PM EDT, May 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Optimi Health Corp

    InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
    Via Investor Brand Network
    News headline image
    Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
    (May 20, 2026) - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and 
    Via PressReach
    Topics Regulatory Compliance
    PsychedelicNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift
    Via Investor Brand Network
    News headline image
    Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
    (April 20, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic 
    Via PressReach
    News headline image
    Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
    Vancouver, British Columbia-March 16, 2026 - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE:8BN) (the "Company" or "Optimi"), a commercial-stage 
    Via PressReach
    Topics Regulatory Compliance
    News headline image
    Optimi Health Completes MD-MA Export for PTSD Treatment Under Australia’s Authorised Prescriber Scheme
    (February 9, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychoactive 
    Via PressReach
    News headline image
    Optimi Health Completes First 2026 Production of MD-MA and Psilo Capsules
    (January 26, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug 
    Via PressReach
    News headline image
    Early Warning Press Release in Accordance with National Instrument 62-103
    Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each... 
    Via Newsfile
    Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson
    Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and... 
    Via PressReach
    News headline image
    Psychedelic Drugs Prove Their Worth In Clinical Trials
    Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
    Via PressReach
    News headline image
    Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
    A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
    Via PressReach
    Topics Cannabis
    Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
    FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
    Via FinancialNewsMedia
    Topics Cannabis
    Optimi Health and ATMA Journey Centers to Send a Clinical Trial Application to Health Canada for Phase I Natural Psilocybin and MDMA
    Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people... 
    Via PressReach
    Topics Supply Chain
    Psychedelics May Make People Less Afraid of Death
    FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change... 
    Via FinancialNewsMedia
    Topics Supply Chain
    Psychedelics Use Among Young Adults Reaches All-Time High
    FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,... 
    Via FinancialNewsMedia
    Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
    FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
    Via FinancialNewsMedia
    Topics Supply Chain
    Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
    Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to... 
    Via FinancialNewsMedia
    Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
    Company utilizes green chemistry to stabilize natural product with higher yields Vancouver, BC – October 5, 2021 – Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”),... 
    Via FinancialNewsMedia
    Topics Intellectual Property
    Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
    Via FinancialNewsMedia
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.